BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
We attended GlaxoSmithKline Pharmaceuticals Ltd.’s virtual analyst meet to understand the business outlook.
Key highlights below -
The Company is working on a three pronged strategy — 1. new introduction in both pharma as well as the vaccines segment, 2. expanding classic vaccines, and 3. growing faster than the market in focus therapies.
While the Covid-19 led disruption had an adverse impact on the company’s performance, the outlook is gradually improving with better medical representative-doctor and doctor-patient connect.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR